| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
ß-pBrPh-Glc targets ice recrystallization. It can control the rate and extent of intracellular ice recrystallization in the nuclei over a broad range of subzero temperatures. It inhibits the growth of extracellular ice and inhibits the recrystallization of intracellular ice. It is an important tool to improve the recovery and function of cryopreserved cells and tissues.
|
|---|---|
| ln Vitro |
In vitro, ß-pBrPh-Glc is a small-molecule ice recrystallization inhibitor. It can control the rate and extent of intracellular ice recrystallization in the nuclei over a broad range of subzero temperatures. It inhibits the growth of extracellular ice and inhibits the recrystallization of intracellular ice. It may also have antioxidant activity.
|
| ln Vivo |
In vivo, ß-pBrPh-Glc is an important tool to improve the recovery and function of cryopreserved cells and tissues. Its ability to control ice recrystallization makes it valuable for cryopreservation applications. No specific therapeutic applications have been reported.
|
| Enzyme Assay |
Cell-free assays for ß-pBrPh-Glc involve ice recrystallization inhibition studies. The compound is tested in ice recrystallization assays where ice crystals are subjected to temperature cycling, and crystal growth is measured microscopically. The inhibition of ice recrystallization is quantified by comparing crystal size in the presence and absence of the compound.
|
| Cell Assay |
Cellular assays for ß-pBrPh-Glc involve cryopreservation studies. Cells are frozen in the presence of ß-pBrPh-Glc, and post-thaw viability and function are assessed. The compound's ability to control intracellular ice recrystallization and improve cell recovery is evaluated.
|
| Animal Protocol |
In vivo animal studies for ß-pBrPh-Glc have not been extensively reported. As a cryopreservation tool, it may be used in studies involving transplantation of cryopreserved cells or tissues. No specific therapeutic animal studies have been described.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ß-pBrPh-Glc are not extensively characterized. Molecular weight: 335.15. LogP: 0.3. Appearance: off-white to light yellow solid powder. Storage: powder at -20°C for up to 3 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicity data for ß-pBrPh-Glc are limited. As a research compound, it is for research use only and not approved for clinical use. Standard laboratory safety precautions should be followed. No specific toxicological studies have been reported.
|
| References |
[1]. Poisson JS, et al. Modulating Intracellular Ice Growth with Cell-Permeating Small-Molecule Ice Recrystallization Inhibitors. Langmuir. 2019 Jun 11;35(23):7452-7458.
|
| Additional Infomation |
ß-pBrPh-Glc is a research compound with potential applications in cryopreservation and cell biology. It is a small-molecule ice recrystallization inhibitor. The compound is available from chemical suppliers. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C12H15BRO6
|
|---|---|
| Molecular Weight |
335.15
|
| Exact Mass |
334.005
|
| CAS # |
30572-42-0
|
| PubChem CID |
7076416
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
0.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
283
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC(=CC=C1OC2C(C(C(C(O2)CO)O)O)O)Br
|
| InChi Key |
XKNTYHQVRMHDHY-RMPHRYRLSA-N
|
| InChi Code |
InChI=1S/C12H15BrO6/c13-6-1-3-7(4-2-6)18-12-11(17)10(16)9(15)8(5-14)19-12/h1-4,8-12,14-17H,5H2/t8-,9-,10+,11-,12-/m1/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-(4-bromophenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~298.4 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (7.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9837 mL | 14.9187 mL | 29.8374 mL | |
| 5 mM | 0.5967 mL | 2.9837 mL | 5.9675 mL | |
| 10 mM | 0.2984 mL | 1.4919 mL | 2.9837 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
